ICON ENERGY CORP. O.N.

ICON has announced an internal review of revenue recognition for 2023–2025, withdrawn its 2025 guidance and postponed quarterly results until no later than April 30, 2026. Analysts see risks: Bank of America cut its rating to Underperform and sharply lowered the price target, Evercore suspended coverage and Jefferies voiced concerns about the order backlog. Preliminary indications from Truist point to possible revenue overstatements of under 2% for 2023 and 2024, which could nonetheless call key earnings and valuation assumptions into question. » More on de.investing.com

ICON has opened the Brian Moran Cancer Institute at Duly Health and Care in Illinois, bolstering the Accellacare site network to support clinical cancer trials. The facility brings 14 medical oncologists, three radiation oncologists and nine surgical specialists and is intended to improve patient access to experimental therapies. ICON describes the expansion as a step to accelerate oncology research and improve patient recruitment, a key barrier to trials. » More on de.investing.com

ClearBridge’s Q3 2025 Mid Cap Strategy letter cited ICON as a key contributor to healthcare-driven outperformance, noting solid gross business wins that expanded its backlog and signaled improvement in clinical research demand. ICON reported Q3 revenue of $2.043 billion, up 0.6% year-on-year, while its stock has fallen over the past month and year. The fund’s outperformance was aided by a Fed rate cut that supported midcap sentiment, with stock selection in healthcare and consumer staples driving results. » More on finance.yahoo.com